Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma

Blood

Volumn 93, Issue 11, 1999, Pages 3913-3921

  Gascoyne, Randy D ^a   Aoun, Patricia ^b   Wu, Daniel ^b   Chhanabhai, Mukesh ^b   Skinnider, Brian F ^b   Greiner, Timothy C ^b   Morris, Stephan W ^b   Connors, Joseph M ^b   Vose, Julie M ^b   Viswanatha, David S ^b   Coldman, Andrew ^b   Weisenburger, Dennis D ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; LACTATE DEHYDROGENASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 2; CHROMOSOME TRANSLOCATION 5; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM;

EID: 0033151520     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.11.3913.411k22_3913_3921     Document Type: Article

References (55)

1. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K: The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848, 1985
2. Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, Sundstrom C, Lennert K, van Unnik JA, Mioduszewska O, Wright DH: Updated Kiel classification for lymphomas [published erratum appears in Lancet 1:372, 1988]. Lancet 1:292, 1988
3. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
4. Tilly H, Gaulard P, Lepage E, Dumontet C, Diebold J, Plantier I, Berger F, Symann M, Petrella T, Lederlin P, Briere J: Primary anaplastic large-cell lymphoma in adults: Clinical presentation, immunophenotype, and outcome. Blood 90:3727, 1997
5. Chott A, Kaserer K, Augustin I, Vesely M, Heinz R, Oehlinger W, Hanak H, Radaszkiewicz T: Ki-1-positive large cell lymphoma. A clinicopathologic study of 41 cases. Am J Surg Pathol 14:439, 1990
6. Agnarsson BA, Kadin ME: Ki-1 positive large cell lymphoma. A morphologic and immunologic study of 19 cases. Am J Surg Pathol 12:264, 1988
7. Kinney MC, Collins RD, Greer JP, Whitlock JA, Sioutos N, Kadin ME: A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol 17:859, 1993
8. Pileri S, Falini B, Delsol G, Stein H, Baglioni P, Poggi S, Martelli MF, Rivano MT, Mason DY, Stansfeld AG: Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1 + with a high content of reactive histiocytes). Histopathology 16:383, 1990
9. Chan JK, Buchanan R, Fletcher CD: Sarcomatoid variant of anaplastic large-cell Ki-1 lymphoma. Am J Surg Pathol 14:983, 1990
10. Mann KP, Hall B, Kamino H, Borowitz MJ, Ratech H: Neutrophilrich, Ki-1-positive anaplastic large-cell malignant lymphoma. Am J Surg Pathol 19:407, 1995
11. Falini B, Liso A, Pasqualucci L, Flenghi L, Ascani S, Pileri S, Bucciarelli E: CD30+ anaplastic large-cell lymphoma, null type, with signet-ring appearance. Histopathology 30:90, 1997
12. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe MJ, Haralambieva E, Pulford K, Pileri S, Morris SW, Mason DY, Delsol G: ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood 91:2076, 1998
13. Piris M, Gatter KC, Mason DY: CD30 expression in follicular lymphoma. Histopathology 18:25, 1991
14. Piris M, Brown DC, Gatter KC, Mason DY: CD30 expression in non-Hodgkin's lymphoma. Histopathology 17:211, 1990
15. Noorduyn LA, de Bruin PC, van Heerde P, van de Sandt MM, Ossenkoppele GJ, Meijer CJ: Relation of CD30 expression to survival and morphology in large cell B cell lymphomas. J Clin Pathol 47:33, 1994
16. Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N, Tassies D, Jaffe ES, Montserrat E, Rozman C, Cardesa A: PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: A highly specific marker of mantle cell lymphoma. Blood 84:2726, 1994
17. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 89:3909, 1997
18. Rimokh R, Magaud JP, Berger F, Samarut J, Coiffier B, Germain D, Mason DY: A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma'). Br J Haematol 71:31, 1989
19. Mason DY, Bastard C, Rimokh R, Dastugue N, Huret JL, Kristoffersson U, Magaud JP, Nezelof C, Tilly H, Vannier JP, Hemet J, Warnke R: CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Br J Haematol 74:161, 1990
20. Kaneko Y, Frizzera G, Edamura S, Maseki N, Sakurai M, Komada Y, Sakurai M, Tanaka H, Sasaki M, Suchi T, Kikuta A, Wakasa H, Hojo H, Mizutani S: A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis. Blood 73:806, 1989
21. Morris SW, Kirstein MN, Valentine MB, Dittmer K, Shapiro DN, Look AT, Saltman DL: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 267:316, 1995
22. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S: Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9:1567, 1994
23. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M, Mori N, Fujimoto J, Miyauchi J, Mikata A, Nanba K, Takami T, Yamabe H, Takano Y, Izumo T, Nagatani T, Mohri N, Nasu K, Satoh H, Katano H, Fujimoto J, Yamamoto T, Mori S: Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity. Blood 86:1954, 1995
24. Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D, Delsol G, Mason DY: Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89:1394, 1997
25. Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P, Rigal-Huguet F, al Saati T, Cerretti DP, Morris SW, Mason DY: A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 89:1483, 1997
26. Weisenburger DD, Gordon BG, Vose JM, Bast MA, Chan WC, Greiner TC, Anderson JR, Sanger WG: Occurrence of the t(2;5)(p23; q35) in non-Hodgkin's lymphoma. Blood 87:3860, 1996
27. Downing JR, Shurtleff SA, Zielenska M, Curcio-Brint AM, Behm FG, Head DR, Sandlund JT, Weisenburger DD, Kossakowska AE, Thorner P, Lorenzana A, Ladanyi M, Morris SW: Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction. Blood 85:3416, 1995
28. Sarris AH, Luthra R, Cabanillas F, Morris SW, Pugh WC: Genomic DNA amplification and the detection of the t(2;5)(p23;q35) in lymphoid neoplasms. Leuk Lymphoma 29:507, 1998
29. Mason DY, Pulford KA, Bischof D, Kuefer MU, Butler LH, Lamant L, Delsol G, Morris SW: Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res 58:1057, 1998
30. Pittaluga S, Wiodarska I, Pulford K, Campo E, Morris SW, Van den Berghe H, De Wolf-Peeters C: The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol 151:343, 1997
31. Wlodarska I, De Wolfe Peeters C, Falini B, Verhoef G, Morris SW, Hagemeijer A, Van den Berghe H: The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma. Blood 92:2688, 1998
32. Arber DA, Sun LH, Weiss LM: Detection of the t(2;5)(p23;q35) chromosomal translocation in large B-cell lymphomas other than anaplastic large cell lymphoma. Hum Pathol 27:590, 1996
33. Greer JP, Kinney MC, Collins RD, Salhany KE, Wolff SN, Hainsworth JD, Flexner JM, Stein RS: Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol 9:539, 1991
34. de Bruin PC, Beljaards RC, van Heerde P, Van Der Valk P, Noorduyn LA, Van Krieken JH, Kluin-Nelemans JC, Willemze R, Meijer CJ: Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology 23:127, 1993
35. Romaguera JE, Manning JT, Jr, Tornos CS, Rodriguez J, Brooks TE, Pugh WC, Ordonez NG, Goodacre AM, Cabanillas F: Long-term prognostic importance of primary Ki-1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large-cell lymphoma. Ann Oncol 5:317, 1994
36. Zinzani PL, Bendandi M, Martelli M, Falini B, Sabattini E, Amadori S, Gherlinzoni F, Martelli MF, Mandelli F, Tura S, Pileri SA: Anaplastic large-cell lymphoma: Clinical and prognostic evaluation of 90 adult patients. J Clin Oncol 14:955, 1996
37. Zinzani PL, Pileri S, Bendandi M, Buzzi M, Sabattini E, Ascani S, Gherlinzoni F, Magagnoli M, Albertini P, Tura S: Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 16:1532, 1998
38. Shiota M, Mori S: The clinicopathological features of anaplastic large cell lymphomas expressing p80NPM/ALK. Leuk Lymphoma 23:25, 1996
39. Nakamura S, Shiota M, Nakagawa A, Yatabe Y, Kojima M, Motoori T, Suzuki R, Kagami Y, Ogura M, Morishima Y, Mizoguchi Y, Okamoto M, Seto M, Koshikawa T, Mori S, Suchi T: Anaplastic large cell lymphoma: A distinct molecular pathologic entity: A reappraisal with special reference to p80(NPM/ALK) expression. Am J Surg Pathol 21:1420, 1997
40. Hutchison RE, Banki K, Shuster JJ, Barrett D, Dieck C, Berard CW, Murphy SB, Link MP, Pick TE, Laver J, Schwenn M, Mathew P, Morris SW: Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood. Ann Oncol 8:37, 1997
41. Connors JM, Klimo P, Fairey RN, Voss N: Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med 107:25, 1987
42. Hoskins PJ, Le N, Gascoyne RD, Klasa R, Shenkier T, O'Reilly SE, Connors JM: Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: Natural history of relapse after initial complete response and prognostic variables defining outcome after relapse. Ann Oncol 8:1125, 1997
43. Vose JM, Anderson JR, Bierman PJ, Bast M, Weisenburger D, Chan WC, Bishop MR, Armitage JO: Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. The Nebraska Lymphoma Study Group. Semin Hematol 31:4, 1994
44. Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, Witte DP: ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14:2175, 1997
45. Karsan A, Gascoyne RD, Coupland RW, Shepherd JD, Phillips GL, Horsman DE: Combination of t(14;18) and a Burkitt's type translocation in B-cell malignancies. Leuk Lymphoma 10:433, 1993
46. Chhanabhai M, Adomat SA, Gascoyne RD, Horsman DE: Clinical utility of heteroduplex analysis of TCR gamma gene rearrangements in the diagnosis of T-cell lymphoproliferative disorders. Am J Clin Pathol 108:295, 1997
47. Chhanabhai M, Britten C, Klasa R, Gascoyne RD: t(2;5) Positive Lymphoma with peripheral blood involvement. Leuk Lymphoma 28:415, 1998
48. ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1995
49. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. Am J Stat Assoc 53:457, 1958
50. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1, 1977
51. Shipp MA, Harrington DP, Anderson JR, Bonadonna G, Brittinger G, Cabanillas F, Canellos GP, Coiffer B, Connors JM, Cowan RA, Crowther D, Dahlberg S, Engelhard M, Fisher RI, Gisselbrecht C, Horning SJ, Lepage E, Lister A, Meerwaldt JH, Montserrat E, Nissen NI, Oken MM, Peterson BA, Tondini C, Velasquez WS, Yeap BY: A predictive model for aggressive NHL: The International non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987, 1993
52. Cox DR: Regression models and life tables. J R Stat Soc 834:187, 1972
53. Shulman LN, Frisard B, Antin JH, Wheeler C, Pinkus G, Magauran N, Mauch P, Nobles E, Mashal R, Canellos G, Tung N, Kadin M: Primary Ki-1 anaplastic large-cell lymphoma in adults: Clinical characteristics and therapeutic outcome. J Clin Oncol 11:937, 1993
54. Kadin ME: Ki-1-positive anaplastic large-cell lymphoma: A clinicopathologic entity? [editorial; comment]. J Clin Oncol 9:533, 1991
55. Pallesen G: The diagnostic significance of the CD30 (Ki-1) antigen. Histopathology 16:409, 1990